BML Inc

Research BML Inc (BMZ) on Bullrun: valuation model: 6.4% undervalued, market cap EUR 727.18M, P/E 17.6, dividend yield 3.5%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerBMZ
• ExchangeMU
• CountryJapan
• SectorHealthcare
• IndustryDiagnostics & Research
• CurrencyEUR
• Valuation signal6.4% undervalued
• Market capEUR 727.18M
• P/E17.6
• Dividend yield3.5%
• Financial periodFY2025
• RevenueEUR 143.19B
• Revenue growth3.8%
• Net incomeEUR 6.26B
• Free cash flow-EUR 849.00M
• Gross margin32.0%

Valuation Snapshot

Bullrun's latest valuation model marks BML Inc as 6.4% undervalued; latest market cap is EUR 727.18M; P/E is 17.6; dividend yield is 3.5%.

About BML Inc

BML, Inc. provides contract clinical testing and related services in Japan. The company offers a range of laboratory testing, such as biochemical and hematologic examination; laboratory test, including tumor markers, infectious diseases, hormones, cellular immunity, genetics, bacteriological tests, and other test;

Frequently asked questions

Is BML Inc overvalued or undervalued?

Bullrun's valuation model currently marks BML Inc as 6.4% undervalued.

What is BML Inc's market cap?

BML Inc's market capitalization is EUR 727.18M.

What is BML Inc's P/E ratio?

BML Inc's price-to-earnings (P/E) ratio is 17.6.

Does BML Inc pay a dividend?

BML Inc has a dividend yield of 3.5%.

What does BML Inc do?

BML, Inc. provides contract clinical testing and related services in Japan. The company offers a range of laboratory testing, such as biochemical and hematologic examination;